Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort

作者：Olsson Tomas^*; Achiron Anat; Alfredsson Lars; Berger Thomas; Brassat David; Chan Andrew; Comi Giancarlo; Eraksoy Mefkure; Hegen Harald; Hillert Jan; Jensen Poul Erik Hyldgaard; Moiola Lucia; Myhr Kjell Morten; Oturai Annette; Schippling Sven; Siva Aksel; Sorensen Per Soelberg; Trampe Anne Kathrin; Weber Thomas; Potts James; Plavina Tatiana; Paes Dominic; Subramanyam Meena; Wiendl Heinz; Dib Hussein; Uren Deniz; Hemmer Bernhard; Buck Dorothea

来源：Multiple Sclerosis, 2013, 19(11): 1533-1538.

DOI：10.1177/1352458513477925

• Multiple sclerosis
• JC virus
• natalizumab
• STRATIFY-JCV
• anti-JCV antibodies
• epidemiology
• infection risk
• international study
• antibody prevalence
• immunosuppressant therapy
• brain infection

JC virus (JCV) is an opportunistic virus known to cause progressive multifocal leukoencephalopathy. Anti-JC virus (Anti-JCV) antibody prevalence in a large, geographically diverse, multi-national multiple sclerosis (MS) cohort was compared in a cross-sectional study. Overall, anti-JCV antibody prevalence was 57.6%. Anti-JCV antibody prevalence in MS patients ranged from approximately 47% to 68% across these countries: Norway, 47.4%; Denmark, 52.6%; Israel, 56.6%; France, 57.6%; Italy, 58.3%; Sweden, 59.0%; Germany, 59.1%; Austria, 66.7% and Turkey, 67.7%. Prevalence increased with age (from 49.5% in patients %26lt; 30 years of age to 66.5% in patients 60 years of age; p %26lt; 0.0001 comparing all age categories), was lower in females than in males (55.8% versus 61.9%; p %26lt; 0.0001) and was not affected by prior immunosuppressant or natalizumab use.

• 出版日期2013-10
• 单位Biogen Idec